The UK’s first needle-free adrenaline nasal spray, EURneffy® 1mg, is now available on prescription for younger children at risk of serious allergic reactions.
The newly available 1 mg dose is licensed for children aged four years and over who weigh 15 kg to less than 30 kg. It extends access beyond the existing 2 mg adult dose, which is intended for adults and children weighing 30 kg or more.
EURneffy® contains 2mg of adrenaline in a single-use nasal spray. It’s designed for adults and children who weigh 30kg or more.
At the first sign of anaphylaxis, the user inserts the nozzle into one nostril and presses the plunger to release the full dose. The adrenaline is absorbed through the nasal lining and enters the bloodstream quickly, even if their nose is congested from hay fever or any other allergies.
Clinical studies and real-world data show that EURneffy® delivers adrenaline just as effectively as an injection, providing the fast response needed in emergencies. *
The spray is compact and ready-to-use. It can also be administered to unconscious patients, as it doesn’t require inhalation. This may help reduce hesitation or panic during a crisis.
EURneffy® 1 mg is now available privately on prescription. Routine NHS access depends on local prescribing and formulary arrangements, so availability may vary between areas.
Some specialist allergy services already prescribe the 2 mg adult dose, which became available in 2025, and some GP practices may also offer it on the NHS. Your GP or allergy specialist can advise on availability in your area.
EURneffy® provides an additional licensed option for the emergency treatment of anaphylaxis. Some people may choose to switch from an adrenaline auto-injector (AAI) after discussing their needs with their GP or allergy specialist, while others may prefer to continue using AAIs.
You do not automatically need to carry both types of device. Follow your clinician’s advice about the most appropriate option for you or your child, and always carry two doses of the prescribed adrenaline treatment.
Listen to our podcast episode with Professor Adam Fox, where we explore how EURneffy® works, who may benefit and what this additional treatment option means for people living with serious allergies.